Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 112

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 2
Chunk 112
---
 million. The current period's G&A expenses include decreases in stock-based compensation expense and personnel costs, offset by increases in professional services, general corporate overhead, and commercial-readiness expenses driven by execution against our expanded business strategy.

Research and development expenses

The following table summarizes our R&D expenses for the periods indicated, together with the changes in those items in terms of dollars and percentage:

39

Nine Months EndedSeptember 30,Change20252024$%Direct program costs:Ovaprene (1)$4,270,154 $7,103,894 $(2,833,740)(40)%Sildenafil Cream (2)678,813 1,105,605 (426,792)(39)%Other advanced clinical stage programs (1)2,165,918 1,009,655 1,156,263 115 %Phase 1 and Phase 1-ready clinical stage programs (1)1,394,982 526,291 868,691 165 %Preclinical stage programs (1)4,878,104 3,232,899 1,645,205 51 %Other development programs— 24,132 (24,132)(100)%Contra R&D expenses (3)(10,713,647)(5,799,795)(4,913,852)85 %Total direct program costs2,674,324 7,202,681 (4,528,357)(63)%Indirect costs:Personnel-related (including stock-based compensation)3,869,767 4,394,329 (524,562)(12)%Outside services (including consulting)21,130 543 20,587 3791 %Facilities-related (including depreciation)55,391 60,344 (4,953)(8)%Other indirect R&D costs161,523 157,526 3,997 3 %Contra R&D expenses(1,880,824)(846,357)(1,034,467)122 %Total indirect R&D costs2,226,987 3,766,385 (1,539,398)(41)%Total R&D expenses$4,901,311 $10,969,066 $(6,067,755)(55)%1.The applicable program(s) receive grant funding and/or the Tax Incentive. The amount of R&D expense for the period indicated is shown on a gross basis (